ReviewCurrent neurology and neuroscience reports2019
Clinical Characteristics of Multiple Sclerosis in African-Americans.
Review in Current neurology and neuroscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.Neurology · 2024Trial
- Real-World, Device-Based Peak Cadence Metrics in Black and White Adults With Multiple Sclerosis.Neurorehabilitation and neural repair · 2026Article
- Disparities in imaging and management of multiple sclerosis: a review.The British journal of radiology · 2026Review
- Multiple Sclerosis: An Ethnically Diverse Disease with Worldwide Equity Challenges Accessing Care.Neurology international · 2025Article
- Advanced Imaging Techniques Use in Giant Cell Arteritis Diagnosis: The Experience at Walter Reed National Military Medical Center.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis.Neurology and therapy · 2025Article
- Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA.Neurology and therapy · 2025Article
- Early intensive therapy versus escalation strategy in French Caribbean multiple sclerosis cohort.European journal of neurology · 2025Article
- The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis.Journal of the neurological sciences · 2024Article
- The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).Journal of neurology · 2024Article
- Review
- Differences in Cardiometabolic Comorbidities Between Black and White Persons Living With Multiple Sclerosis.Archives of physical medicine and rehabilitation · 2022Article
- Lessons Learned From an Integrated Neurology Diversity, Equity, and Inclusion Curriculum.Neurology. Clinical practice · 2021Article
- Structural disconnectivity from paramagnetic rim lesions is related to disability in multiple sclerosis.Brain and behavior · 2021Article
- How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity.Neurology. Clinical practice · 2021Article
- Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy.Frontiers in neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMultiple sclerosis (MS) is an autoimmune disease of the central nervous system that affects nearly 1 million people in the USA and has the potential to profoundly affect physical ability and income potential at a young age. Since a landmark paper was published in 2014, few studies have looked at differences in MS disease characteristics between African-American and Caucasian patients. RECENT
findingsAfrican-American patients often have a more severe MS disease course, as well as biomarker data which can portend a worse prognosis. While the sample sizes are usually quite small, subgroup analyses of African-American patients have been performed to evaluate efficacy of disease-modifying treatments as compared with the entire study population, made up of primarily Caucasians. In an era where we strive for personalized medicine, understanding racial differences in MS may help us better treat African-American patients in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.